Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation | Synapse
April 14, 2026
Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation
Key Points
The aim is to develop a nanoemulsion-based gel formulation containing dexlansoprazole and evaluate its performance.
Developed dex-lansoprazole-loaded nanoemulsion (DXL-NE)
Conducted in vitro dissolution studies
Planned ex vivo evaluations of the formulation
DXL-NE showed improved in vitro dissolution compared to conventional forms
Indicates potential enhancement in bioavailability
Further in vivo studies needed to confirm findings
Abstract
The developed DXL-loaded NE improved in vitro dissolution, indicating potential enhancement of bioavailability, which requires confirmation through comprehensive in vivo studies.